Global
Studies examine cannabis use and chronic pain in dialysis patients
Research published in 2026 highlights the need to distinguish correlation from causation in clinical evidence.
Two clinical studies published in 2026 have investigated the relationship between cannabis use and chronic pain in patients undergoing dialysis. A cross-sectional observational study of 186 male patients analysed cannabis smoking and pain severity. However, researchers emphasise that these observational findings cannot establish a causal therapeutic relationship.
Key findings from the 2026 research
Observational study design
A 2026 study in Scientific Reports analysed cannabis smoking and chronic pain severity in 186 male dialysis patients.
No causal link proven
Because the research was observational rather than a randomised controlled trial, it cannot prove that cannabis treats pain.
Separate hemodialysis data
A distinct study published in Kidney360 also investigated cannabis use among chronic pain patients receiving maintenance hemodialysis.
Our view
The design of these studies determines what may be concluded from them. A cross-sectional observational study can show that cannabis use and pain severity are associated; it cannot show that one causes the other. Patients in more pain may be more likely to use cannabis, which would produce the same association. We therefore do not present this as evidence that cannabis treats pain in dialysis patients. It is a reason for controlled trials to be conducted, and it is useful to clinicians as a picture of what patients are already doing.
Background
Clinical understanding of cannabis use in patients undergoing dialysis remains limited. In 2026, researchers sought to evaluate how cannabis smoking relates to chronic pain severity within this specific patient group. This prompted the publication of separate observational studies in Scientific Reports and Kidney360.
Sources
Get the latest medical cannabis news by email
We send AMI updates and research summaries once a week.
